(Editor: Jiang Rong)
The chemical name
‘s research report has been published in the medical journal, the Karen library.
researchers from the United States and other countries analyzed 7 randomized controlled trials of more than 4000 patients with metastatic breast cancer. The results showed that Avastin could not prolong the survival time of patients. An investigation of the patient’s physical condition and satisfaction with daily life also showed that the patient had not improved after taking avastin.
the United States Food and Drug Administration approved Avastin for breast cancer treatment in 2008. However, clinical trials show that Avastin does not prolong the survival of patients with breast cancer, and has obvious side effects, including elevated blood pressure, fatigue, white blood cell abnormalities, etc.. In November last year, the Council revoked Avastin for breast cancer on the grounds of insecurity and invalidity. Avastin can still be used for the treatment of lung cancer, kidney cancer, colon cancer and rectal cancer.
of Avastin as bevacizumab, a monoclonal antibody drugs. Its research and development theory, the drug by inhibiting vascular endothelial growth factor to block the blood supply to the tumor, so that the tumor cells can not spread in the body, and can effectively play the role of chemotherapy.
, a new study of the world’s best-selling cancer drug Avastin, shows that the drug does not extend the lives of patients with breast cancer, but also can not improve the quality of life of patients.